Pubblicazioni

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma. A “real world” experience

2022 - LEUKEMIA RESEARCH REPORTS
Fucci, Ludovica; Gensini, Lorenzo; Coppetelli, Ugo; Ortu La Barbera, Elettra; Gentile, Martina; Fiori, Luciano; Perrone, Salvatore; Cimino, Giuseppe

Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis

2021 - ONCOIMMUNOLOGY
Naicker, Serika D; Feerick, Claire L; Lynch, Kevin; Swan, Dawn; Mcellistrim, Cian; Henderson, Robert; Leonard, Niamh A; Treacy, Oliver; Natoni, Alessandro; Rigalou, Athina; Cabral, Joana; Chiu, Christopher; Sasser, Kate; Ritter, Thomas; O'Dwyer, Michael; Ryan, Aideen E

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide

2020 - CANCER IMMUNOLOGY, IMMUNOTHERAPY
Sarkar, Subhashis; Chauhan, Sachin K S; Daly, John; Natoni, Alessandro; Fairfield, Heather; Henderson, Robert; Nolan, Emma; Swan, Dawn; Hu, Jinsong; Reagan, Michaela R; O'Dwyer, Michael

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma